Some thoughts on the Doliprane case

The announcement by Sanofi of the sale of 50% of the capital of its subsidiary Opella - which markets Doliprane - to the American investment fund Clayton Dubilier & Rice, aroused numerous reactions. How to combine France's attractiveness for foreign investments with the protection of our national sovereignty?

‍

Discover below the article by Renée Kaddouch, which outlines answers to this delicate question for Décideurs Magazine.